Resources for Religious Leaders and Faith Communities
The Climate Action Tracker (CAT) is an independent scientific analysis produced by two research organisations tracking climate action since 2009. We track progress towards the globally agreed aim of holding warming well below 2°C, and pursuing efforts to limit warming to 1.5°C.
The marathon to eradicate polio is on its final lap: the world is more than 99% of the way to success. After millennia of living with poliovirus and suffering the paralysis it causes, today nearly all the world’s people live in polio-free countries; two of the three strains of wild poliovirus (WPV...) have been eradicated. Some 20 million people are walking who would have been paralysed had it not been for the efforts of national governments and health workers. If eradicating polio has been a marathon, the finishing line is in sight.
more
The marathon to eradicate polio is on its final lap: the world is more than 99% of the way to success. After millennia of living with poliovirus and suffering the paralysis it causes, today nearly all the world’s people live in polio-free countries; two of the three strains of wild poliovirus (WPV...) have been eradicated. Some 20 million people are walking who would have been paralysed had it not been for the efforts of national governments and health workers. If eradicating polio has been a marathon, the finishing line is in sight.
more
The strengthened plan aims to achieve and sustain a polio-free world through a focus on implementation and accountability. Emphasis will be on cutting outbreak response times; increasing vaccine demand; transforming campaign effectiveness; working systematically through integration; increasing acce...ss in inaccessible areas; transitioning towards government ownership; and improving decision-making and accountability.
more
The strengthened plan aims to achieve and sustain a polio-free world through a focus on implementation and accountability. Emphasis will be on cutting outbreak response times; increasing vaccine demand; transforming campaign effectiveness; working systematically through integration; increasing acce...ss in inaccessible areas; transitioning towards government ownership; and improving decision-making and accountability.
more
This is a summary of the following peer-reviewed, scientific article:
Comparative Evaluation of Immunoassays to Improve Access to Diagnosis for Chagas Disease in Colombia.
To support its R&D activities on Chagas disease, DNDi launched the Chagas Clinical Research Platform (CCRP). The platform brings together partners, experts, and stakeholders to provide support for evaluation and development of new treatments for Chagas disease. The patient-centred platform aims to f...acilitate clinical research, provide a forum for technical discussions, develop a critical mass of expertise, and strengthen institutional research capacities. In addition, it identifies and reviews priority needs, works towards standardization of methodology to assess drug efficacy and reviews alternatives for using current approved drugs (new schemes, doses, combination) and special scenarios (resistance).
more
Chagas is a parasitic disease that affects over 6 million people in the
world. As the disease typically remains asymptomatic for years, new cases
often go unnoticed and unreported, and most people with the disease
are unaware of their condition. Less than 10% of people affected are
diagnosed and... the vast majority do not receive the treatment they need.
If not treated, Chagas may cause irreversible, life-threatening damage to
the heart and other vital organs.
more
At the forefront of DNDi’s efforts to develop new treatments is the need to understand the realities and treatment needs of patients and health care staff in the field. The ultimate goal for human African trypanosomiasis (HAT) is a truly simplified
treatment which can be orally administered, impl...emented at the primary health care level, and effective against both stages of the disease.
more
DNDi’s long-term goal for sleeping sickness, also known as human African trypanosomiasis (HAT), is to develop and register two new drugs that are effective against both Stage 1 and Stage 2 of the disease and both subspecies of the parasite, T.b. gambiense and T.b. rhodesiense. T.b. rhodesiense is ...an acute form of the disease, occurring primarily in Eastern and Southern Africa. Better treatments for T.b. rhodesiense sleeping sickness are urgently needed.
more
DNDi is now striving to make fexinidazole available to the majority of people who have T.b. gambiense sleeping sickness. We are supporting a three-year access and pharmacovigilance study that began in 2020 and have so far carried out in-country training of relevant staff in 250 hospitals and... health centres in T.b. gambiense-endemic countries; and updated national treatment and pharmacovigilance guidelines in Angola, Central African Republic, the Democratic Republic of Congo, Equatorial Guinea, Guinea, and Chad.
more
La enfermedad de Chagas es parasitaria y afecta a más de 6 millones
de personas en el mundo. Como normalmente es asintomática durante
años, los nuevos casos suelen no detectarse ni reportarse y la mayoría
de las personas con la enfermedad no tiene conciencia de su condición.
Se diagnostica ...a menos del 10% de las personas afectadas, y en su gran
mayoría estas no reciben el tratamiento que necesitan. Sin tratamiento,
la enfermedad de Chagas puede causar daños irreversibles al corazón y
otros órganos vitales, o la muerte.
more
Full Perscribing information on Fexinidazole Tablet for oral use
INDICATIONS AND USAGE
Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in pati...ents 6 years of age and older and weighing at least 20 kg.
Limitations of Use
Due to the decreased efficacy observed in patients with severe second stage HAT (cerebrospinal fluid white blood cell count (CSF-WBC) >100 cells/μL) due to T. brucei gambiense disease, Fexinidazole Tablets should only be used in these patients if there are no other available treatment options [see Warnings and Precautions (5.1)]
more
Leishmaniasis is a climate-sensitive disease. Changes in
temperature, rainfall, and humidity can have strong impacts on
the sandfly vector, altering their distribution and influencing their
survival and population sizes. Increased temperatures shorten
vector development time, reduce Leishmania p...arasite incubation
time, and increase vector biting rates, allowing transmission
in areas not previously endemic for the disease. Poor and
marginalized communities will be hit disproportionately harder by
the effects of climate change, and droughts, famines, and floods
can also lead to displacement and migration of immunologically
naive people to areas where leishmaniasis is endemic, posing a
threat of leishmaniasis outbreaks.
more
La leishmaniasis es una enfermedad tropical desatendida sensible
al clima, trasmitida por la picadura de insectos flebótomos y
se calcula que amenaza a mil millones de personas en todo el mundo.
Esta enfermedad altamente compleja se presenta de varias formas
clínicas, causadas por 20 especies ...del parásito Leishmania.
more
Mycetoma is a slow-growing bacterial or fungal infection, most often of the foot, that may spread to other parts of the body and can cause severe deformity. It is a debilitating disease that most often affects poor people in rural areas with limited access to health care.
In 2018, we are celebrating 20 years of progress in eliminating trachoma, the world’s leading infectious cause of blindness. Set up in 1998 by Pfizer Inc. and the Edna McConnell Clark Foundation, the International Trachoma Initiative (ITI) supports Ministries of Health in over 30 countries around ...the world by making Zithromax® available for use in public health campaigns to eliminate trachoma. The 20th anniversary of our founding gives us an opportunity to reflect on the distance we’ve traveled in fighting this disease, and raise the ambition for accelerating to a world where diseases like trachoma are a distant memory. We have not traveled alone these past 20 years – a broad coalition of actors including NGOs, the World Health Organization (WHO), Ministries of Health, health workers, and community members have made these incredible achievements possible. Our 20th anniversary gives us an opportunity to celebrate this coalition of partners, colleagues, and friends
more
Visceral leishmaniasis, the most severe form of leishmaniasis also known as kala-azar, is a life-threatening disease caused by Leishmania parasites which are transmitted by female sandflies. Visceral leishmaniasis causes fever, weight loss, spleen and liver enlargement, and, if not treated, death. P...eople with both visceral leishmaniasis and HIV are particularly difficult to cure.
more
Cutaneous leishmaniasis is a painful disease that exerts a serious toll on societies around the world that are afflicted by it. Although not life-threatening, the skin ulcers and scars it causes can lead to isolation and psychosocial pathologies due to social stigma, and its occurrence is often asso...ciated with regional conflicts.
more